There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on MoonLake Immunotherapeutics (MLTX – Research Report), MDxHealth S.A. Sponsored ADR (MDXH – Research Report) and Poseida Therapeutics (PSTX – Research Report) with bullish sentiments.
MoonLake Immunotherapeutics (MLTX)
In a report released yesterday, Julian Harrison from BTIG maintained a Buy rating on MoonLake Immunotherapeutics, with a price target of $68.00. The company’s shares closed last Monday at $58.09, close to its 52-week high of $63.40.
According to TipRanks.com, Harrison is a 3-star analyst with an average return of
MoonLake Immunotherapeutics has an analyst consensus of Strong Buy, with a price target consensus of $70.50, implying a 17.7% upside from current levels. In a report issued on October 1, Cantor Fitzgerald also maintained a Buy rating on the stock with a $65.00 price target.
See the top stocks recommended by analysts >>
MDxHealth S.A. Sponsored ADR (MDXH)
BTIG analyst Mark Massaro reiterated a Buy rating on MDxHealth S.A. Sponsored ADR yesterday and set a price target of $7.00. The company’s shares closed last Monday at $2.36, close to its 52-week low of $2.15.
According to TipRanks.com, Massaro has 0 stars on 0-5 stars ranking scale with an average return of
MDxHealth S.A. Sponsored ADR has an analyst consensus of Moderate Buy, with a price target consensus of $7.50.
Poseida Therapeutics (PSTX)
BTIG analyst Justin Zelin reiterated a Buy rating on Poseida Therapeutics yesterday and set a price target of $12.00. The company’s shares closed last Monday at $2.25, close to its 52-week low of $1.54.
According to TipRanks.com, Zelin is a 1-star analyst with an average return of
Poseida Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $13.67.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MLTX:
- Beneficial owner of MoonLake Immunotherapeutics Bihua Chen buys $17M in shares
- MoonLake Immunotherapeutics to present Phase 2 MIRA trial data for sonelokimab
- Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress
- MoonLake Immunotherapeutics downgraded to Neutral from Buy at Bryan Garnier
- Scinai Immunotherapeutics announces results from preclinical NanoAbs study
